Dec 20 2017 Posted: 14:32 GMT

Highlights from the American Society of Hematology meeting 2017 - BCNI's CyborD-DARA study

The World Myeloma Forum selected BCNI's Phase 1b CyborD-DARA study as one of the highlights of the American Society of Hematology (ASH)meeting in Atlanta in December.

See Prof Michael O'Dwyer talk about  how weekly CyborD-Dara is a safe and effective upfront treatment for newly diagnosed multiple myeloma and the excellent progress being achieved in this study.

See video here

PreviousNext